Azitra, Inc. (AZTR)

Quarterly Report Filed: 2026-05-13

Company has conducted multiple capital raises including a Series A preferred stock offering (March 2026), private placements, and follow-on public offerings, indicating aggressive fundraising but also potential shareholder dilution concerns.
Filing shows significant warrant issuances across multiple offerings (Class A, Series B, Series C, and common warrants), suggesting the company is using equity instruments to preserve cash but creating future dilution and potential downward price pressure.
Presence of an ELOC (Equity Line of Credit) facility with Alumni Capital as of Q1 2026 indicates the company may have liquidity constraints and is relying on equity financing arrangements rather than traditional debt or operating cash flow.
Multiple follow-on public offerings and private placements within a short timeframe (January-April 2026) suggest the company is burning through capital rapidly and may face pressure to achieve key milestones to justify valuations to investors.

Current Report Filed: 2026-05-13

Azitra announced Q1 2026 financial results on May 13, 2026, via press release, indicating the company is actively reporting operational performance to investors and the market.
The filing was signed by Francisco D. Salva as Chief Executive Officer, confirming continuity in leadership and executive authorization of financial disclosures.
As an emerging growth company, Azitra has elected to use the standard transition period for accounting standards compliance, which may provide some flexibility in financial reporting requirements compared to larger public companies.

Insider Trading Filed: 2026-04-22

Travis Whitfill, Chief Operating Officer and Director, received a stock option grant of 64,300 shares at an exercise price of $0.2127, granted on 04/20/2026 with a 10-year expiration, indicating the company is using equity compensation for executive retention.
The option vests over 3 years with 1/3 vesting at one year and then 1/36 monthly thereafter, a standard vesting schedule that aligns executive incentives with long-term company performance and reduces immediate dilution concerns.
This is an option grant rather than a direct stock purchase, suggesting no immediate insider confidence signal about the stock's current valuation, though it does represent a meaningful equity stake for the COO.

Insider Trading Filed: 2026-04-22

Francisco D. Salva, President and CEO, received a grant of 220,879 stock options on 04/20/2026 with an exercise price of $0.2127, indicating the company's current valuation near this price point.
The options follow a standard 3-year vesting schedule (1/3 after one year, then monthly over 24 months), which is typical for executive compensation and aligns management incentives with long-term company performance.
As the CEO and a 10% owner, Salva's option grant represents continued equity participation in the company, though this is a standard compensation arrangement rather than discretionary insider buying, which could suggest confidence in future prospects.
No sale or disposition of existing securities is reported, indicating the CEO is not reducing his position in the company during this filing period.

Insider Trading Filed: 2026-04-22

CFO Norman Staskey received a stock option grant of 35,524 shares at an exercise price of $0.2127, suggesting the company is using equity compensation to retain executive talent.
The option has a 10-year expiration (04/20/2036) with a 3-year vesting schedule (1/3 at one year, then monthly vesting), indicating a medium-term incentive alignment with company performance.
The relatively modest option grant size and low exercise price may reflect either early-stage valuation challenges or modest compensation positioning for the CFO role at this small-cap biotech company.
This is a routine equity grant transaction with no indication of insider selling pressure or confidence signals from significant stock purchases by the reporting person.

Current Report Filed: 2026-03-23

Azitra, Inc. has raised $31.4 million through a private placement of convertible preferred stock and warrants. This capital will be used for research and development, general corporate expenses, and working capital needs.
The convertible preferred stock will not be convertible into common stock until Azitra's shareholders approve an increase in authorized shares and the issuance of the conversion shares.
The warrants issued in the private placement have an exercise price of $0.123 per share and will become exercisable after shareholder approval and filing of a certificate of amendment.

Insider Trading Filed: 2026-03-20

The reporting person, Francisco D. Salva, is the President and CEO of Azitra, Inc., indicating high-level insider involvement.
Salva acquired 500 shares of Series A Convertible Non-Redeemable Preferred Stock, as well as 4,064,050 Series B and Series C Warrants, suggesting potential future investment in the company.
The conversion of the Series A Preferred Stock and exercise of the Series B and C Warrants are subject to shareholder approval, which could be a key milestone for the company.

Current Report Filed: 2026-03-05

Azitra, Inc. withdrew the proposals described in its January 2, 2026 proxy statement and canceled the scheduled special meeting of stockholders, indicating a change in the company's plans.
The company cited a lack of quorum at the previously adjourned special meeting as the reason for withdrawing the proposals and canceling the meeting.
The cancellation of the special meeting suggests a potential delay or change in the company's strategic initiatives, which may impact investor sentiment.

Annual Report Filed: 2026-02-27

Azitra, Inc. (AZTR) filed its FY 2025 10-K report, providing financial and operational details for the year.
The company appears to have raised capital through multiple follow-on public offerings and private placements in 2024 and 2025.
Azitra reported intangible asset growth, including increased investments in patents and trademarks, which could indicate R&D focus.

Current Report Filed: 2026-02-27

Azitra, Inc. reported its financial results for the year ended December 31, 2025, indicating the company's performance during this period.
The filing does not provide any details on Azitra's financial performance, revenue trends, margins, or guidance, limiting the ability to assess the company's overall condition.
Without additional financial information or details on any material business developments, it is difficult to determine the significance of this 8-K filing for investors.

Current Report Filed: 2026-02-06

Azitra, Inc. was unable to achieve a quorum at its special stockholder meeting held on February 6, 2026, and has adjourned the meeting to March 6, 2026.
The record date for determining stockholders entitled to vote at the adjourned special meeting remains the close of business on January 2, 2026.
No changes have been made to the proposals to be voted on by stockholders at the special meeting.

Important Information